FDA approves HPV Vaccine for adults over 26 and up to 45 in an effort to reduce HPV-caused cancers Events, Seminars, & Publications 22. 10. 2018 The US Food and Drug Administration expanded its approval of the HPV vaccine to include women and men up to 45-year-old, in an effort to protect more people from several types of cancer -including cervical cancer- caused by the human papillomavirus. The vaccine “Gardasil 9” prevents infection from the high-risk HPV types and until now it was approved for people ages 9 to 26. The vaccine also protects against low-risk HPV types associated with most cases of genital warts. The “approval represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. HPV infections are common, most sexually active women and men will become infected with HPV in their lifetimes. In most cases, the virus is cleared naturally by the body’s immune system. Sometimes that doesn’t occur and some people develop a lasting infection. Over the course of many years, the HPV infection transforms normal cells into precancerous lesions or cancer. In the U.S. about 4,000 women die from cervical cancer each year and the burden is much higher globally. “High risk” HPV types also are associated with vulvar, vaginal, anal, penile, and many head and neck cancers. Gardasil 9, which protects against nine HPV strains, is typically given in two doses, several months apart, to children 9 to 14, and in three doses for young people 15 to 26. For those older than 26, the recommended regimen will be three doses. Experts say Gardasil 9 is most effective when administered before the initiation of sexual activity. However, data indicate that the vaccine can benefit the older people because even though many adults have been exposed to some types of HPV, most have not been exposed to all nine types covered by the vaccine. Sources: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622715.htm https://www.washingtonpost.com/health/2018/10/05/fda-approves-hpv-vaccine-people-up/?noredirect=on&utm_term=.c2166d33d9f5 Tags: HPV , prevention , cervical cancer
Health Innovation Ecosystems Events, Seminars, & Publications 25. 03. 2024 We sincerely thank the Hellenic Digital Health Cluster-HDHC for the invitation to present the contribution of mycancer at the event, entitled «Health Innovation Ecosystems» addressing the challenges o...[Read more]
Webinar: Prevention and early diagnosis of cancer, new therapeutic approaches Events, Seminars, & Publications 16. 07. 2024 The seminar is addressed to health professionals, who are an integral part of the interdisciplinary approach, aiming at the Prevention and Early diagnosis of cancer and the Therapeutic treatment and c...[Read more]
Oral yeast infections: what can they indicate? Events, Seminars, & Publications 07. 11. 2023 Professor Ourania Nicolatou-Galitis had the honor of presenting “Oral fungal infections and the secrets they may hide” at the Conference of the Hellenic Society of Medical Mycology, October 19, 2023. ...[Read more]